IUI vs. IVF: Which Fertility Treatment Is Right for You?
The American Society for Reproductive Medicine defines infertility as the failure to achieve pregnancy after 12 months of unprotected intercourse — or six months for women over 35. For patients who reach that threshold, one of the first clinical decisions is whether IUI or IVF is the appropriate starting point. The answer depends on age, diagnosis, sperm parameters, fallopian tube status, and ovarian reserve — not a default protocol.
Understanding the clinical differences between IUI and IVF helps patients have a more productive first conversation with a specialist. The two treatments work through fundamentally different mechanisms, suit different patient profiles, and carry meaningfully different success rates depending on the clinical picture.
Damien Fertility Partners has provided IVF and IUI treatment across New Jersey since 1989, with offices in Shrewsbury (Monmouth County), Newark (Essex County), and Jersey City (Hudson County). Our embryology lab holds accreditation from the College of American Pathologists (CAP), the FDA, and the NJ State Department of Health — all with zero deficiencies. Each patient works with the same ABOG board-certified reproductive endocrinologist from consultation through treatment.
How IUI Works
Intrauterine insemination (IUI) is a minimally invasive, in-office procedure that requires no anesthesia. Washed and concentrated sperm is placed directly into the uterine cavity using a small catheter, shortening the distance sperm must travel to reach the egg. IUI is typically combined with ovarian stimulation medications to improve the chances of successful fertilization.
The procedure takes approximately 15 to 20 minutes. Most patients resume normal activity the same day, with mild cramping being the most commonly reported side effect. Because IUI works with the body’s natural fertilization process, it is the lower-intervention option when clinical factors suggest it has a reasonable probability of success.
IUI is lower in cost than IVF and typically requires less monitoring. For patients who are appropriate candidates, it is an evidence-based starting point — not a consolation path.
How IVF Works
In vitro fertilization (IVF) is a multi-step process involving ovarian stimulation, egg retrieval, laboratory fertilization, embryo development, and transfer. The full cycle — from the start of stimulation through transfer — takes approximately three weeks for a fresh cycle, though frozen embryo transfers (FET) allow more scheduling flexibility.
Ovarian stimulation. Injectable medications prompt the ovaries to develop multiple follicles over roughly 10 to 14 days. Progress is tracked through ultrasound and bloodwork, with medication adjusted in real time based on response.
Egg retrieval. When follicles reach target size, a trigger shot signals final egg maturation. Retrieval is performed under light sedation by our in-house surgical team — a brief, ultrasound-guided procedure. Patients are not referred out for this step.
Fertilization and embryo development. Eggs are fertilized in our CAP-accredited embryology lab. Development is tracked continuously through CHLOE by Fairtility, an AI-powered monitoring system integrated into embryoscope time-lapse incubators. CHLOE provides continuous, non-invasive developmental data to inform which embryos are best suited for transfer.
Embryo transfer. The transfer is a brief, in-office procedure that does not require anesthesia. Optional preimplantation genetic testing (PGT-A) can be performed before transfer to evaluate chromosomal integrity — particularly relevant for patients with recurrent pregnancy loss or a known heritable condition.
IVF offers a higher degree of control over the fertilization and selection process than IUI can provide. For patients with more complex diagnoses, it delivers clinical tools that IUI cannot replicate.
Candidates for IUI
IUI tends to be most effective for patients with open fallopian tubes, near-normal sperm parameters, and responsive ovulation. For women under 38 with unexplained infertility, a systematic review in the Archives of Gynecology and Obstetrics found no significant difference in live birth rates between IUI with ovarian stimulation and IVF in treatment-naïve patients. For the right candidate, IUI is an evidence-based starting point — not a lesser alternative.
Age is a central variable. The CDC recommends that women 35 and older seek fertility evaluation after six months of trying to conceive, and that women over 40 pursue evaluation and treatment more immediately. For younger patients without structural or severe male factor issues, IUI offers a clinically sound, lower-intervention path before escalating to IVF.
ASRM clinical guidelines support IUI as a first-line option in appropriate cases of ovulatory dysfunction, mild male factor infertility, and unexplained infertility in younger patients.
Cases where IVF Becomes the Recommended Path
Certain clinical factors make IUI unlikely to succeed and shift the recommendation clearly toward IVF. These include moderate to severe male factor infertility — where IVF with intracytoplasmic sperm injection (ICSI) can assist fertilization in ways IUI cannot — blocked or damaged fallopian tubes, endometriosis affecting tubal function, prior failed IUI cycles, or age-related urgency.
A BMC Women’s Health literature review supports transitioning to IVF for women over 38 and for couples who have not achieved pregnancy after IUI. A 2024 meta-analysis in Human Reproduction Update reinforces that the transition should be based on individual clinical factors — not a default assumption that IVF is always faster or more effective.
IVF is also the appropriate path when genetic testing of embryos is clinically indicated — for example, when one or both partners carry a known heritable condition, or when recurrent pregnancy loss suggests chromosomal factors may be involved. In these cases, IVF with PGT-A provides a layer of evaluation before transfer that IUI cannot offer.
IVF Outcomes: 2023 SART Reported Data
IVF success rates in the U.S. are reported annually to the CDC through the National ART Surveillance System (NASS) and independently published by SART. In 2023 — the most recent SART reporting year — we reported an 81.8% live-birth rate per new patient for women under 35, with a 100% elective single-embryo transfer (eSET) rate in that age group. Clinic-to-clinic comparisons should be interpreted with caution due to differences in patient populations. Full outcomes data across all age brackets is available on the SART website and our success rates page.
The 100% eSET rate carries important context: strong live-birth outcomes were achieved while actively minimizing the risk of twin or higher-order pregnancies — which carry elevated health risks for both mother and child. That clinical approach is what makes our numbers meaningful.
CAP-Accredited Embryology Lab and AI Monitoring
IVF outcomes are closely tied to lab quality. Our embryology lab holds accreditation from the College of American Pathologists (CAP), the FDA, and the NJ State Department of Health — all with zero deficiencies. It is directed by Klaus Wiemer, PhD, HCLD, who brings over 40 years of clinical embryology experience and has authored more than 80 peer-reviewed publications.
The lab uses CHLOE by Fairtility for AI-powered embryo monitoring. Built into embryoscope time-lapse incubators, CHLOE tracks embryo development continuously and non-invasively, giving the embryology team real-time data to support transfer decisions without removing embryos from the controlled environment.
The Physicians Making These Decisions
Every IUI and IVF recommendation at our practice comes from a board-certified reproductive endocrinologist — not a nurse coordinator, not a rotating provider.
Dr. Miguel Damien founded the practice in 1989, originally as East Coast IVF — establishing New Jersey’s first successful IVF program in Monmouth and Ocean County. A Dartmouth Medical School graduate, he completed his OB/GYN residency and REI fellowships at Harvard Medical School and the University of Connecticut. Board-certified in REI by ABOG and fluent in Spanish, he has been named a Castle Connolly Top Doctor in the NY Metro Area six times (2005, 2007, 2008, 2010, 2017, 2018).
Dr. Barry Perlman is an ABOG board-certified REI specialist and Fellow of the American College of Obstetricians and Gynecologists (ACOG). A published researcher on endocrine disruptors and fertility, he has been named a Castle Connolly Top Doctor five times. He joined our practice in 2023 and offers both in-person and virtual consultations.
Inclusive Care for All Patients
Damien Fertility Partners is committed to inclusivity in reproductive care, providing support and services for a wide range of family-building paths. Whether patients are individuals, couples, LGBTQ+ families, or those pursuing single parenthood, the practice approaches every journey with equal care and respect.
Spanish-speaking providers are available at all three offices, and Dr. Damien is fluent in Spanish.
The 2024 Murphy expansion of New Jersey’s fertility insurance mandate requires group health plans covering 50 or more employees to cover up to four completed egg retrievals per lifetime, with prior restrictions on age, relationship status, and sexual orientation removed. Patients whose employers fall under this mandate may have coverage for IVF regardless of diagnosis.
Schedule a Consultation with Dr. Damien or Dr. Perlman
The IUI vs. IVF decision begins with a thorough evaluation by a board-certified reproductive endocrinologist. At our practice, that evaluation covers age, diagnosis, sperm parameters, fallopian tube status, ovarian reserve, and treatment history — forming the basis of a recommendation tailored to your specific clinical picture.
We see patients at our offices in Shrewsbury (Monmouth County), Newark (Essex County), and Jersey City (Hudson County). Dr. Perlman offers virtual consultations for patients who prefer to begin remotely. Visit damienfertilitypartners.com or call (732) 758-6511 to request an appointment with Dr. Damien or Dr. Perlman.
Frequently Asked Questions
1. What is the main difference between IUI and IVF?
IUI places prepared sperm directly into the uterus, allowing fertilization to occur inside the body. IVF retrieves eggs from the ovaries, fertilizes them in a CAP-accredited lab, and transfers a resulting embryo into the uterus. IVF involves more steps, greater medical intervention, and typically higher success rates for patients with complex diagnoses — but is not the clinically appropriate starting point for every patient.
2. Is IUI less effective than IVF?
Not necessarily for the right patient. A systematic review in the Archives of Gynecology and Obstetrics found no significant difference in live birth rates between IUI with ovarian stimulation and IVF for treatment-naïve women under 38 with unexplained infertility. For patients with more complex diagnoses or age-related factors, IVF generally offers higher per-cycle success rates. The American Society for Reproductive Medicine supports IUI as a clinically appropriate first-line option in suitable cases.
3. How many IUI cycles should I try before moving to IVF?
This depends on age, diagnosis, and response to treatment. Many physicians recommend reassessing after two to three IUI cycles, particularly for women over 35. At our practice, your physician will review your response and recommend next steps based on your specific clinical picture — not a fixed cycle threshold.
4. What is CHLOE, and how does it affect IVF outcomes?
CHLOE by Fairtility is an AI-powered embryo monitoring system integrated into embryoscope time-lapse incubators in our embryology lab. It tracks embryo development continuously and non-invasively, giving our team real-time data to support embryo selection decisions — without disturbing the embryos or removing them from the incubator environment.
5. Can IUI or IVF be used with donor sperm?
Yes. Both IUI and IVF can be performed using donor sperm, making them accessible options for single individuals and LGBTQ+ patients. Our practice offers donor sperm IUI, reciprocal IVF, and dedicated support for all family-building paths, with no BMI-based limitations on care.
6. What are your IVF success rates?
In 2023, we reported an 81.8% live-birth rate per new patient for women under 35, with a 100% eSET rate in that age group, as submitted through SART. Full outcomes data across all age groups is available on the SART website and our success rates page. Clinic-to-clinic comparisons should be interpreted with caution due to differences in patient populations.
7. How do I know which treatment is right for me?
The only reliable way to determine whether IUI or IVF is appropriate is through a thorough evaluation by an ABOG board-certified reproductive endocrinologist. At our practice, that evaluation covers age, diagnosis, sperm parameters, fallopian tube status, ovarian reserve, and treatment history — forming the basis of a recommendation grounded in your specific clinical picture, not a standardized protocol.